PUBLISHER: The Business Research Company | PRODUCT CODE: 1730963
PUBLISHER: The Business Research Company | PRODUCT CODE: 1730963
Netherton syndrome is a rare genetic condition caused by mutations in the SPINK5 gene, resulting in red, scaly skin, brittle hair, and a heightened susceptibility to infections. This disorder affects the skin barrier and immune system, leading to chronic skin inflammation and allergic reactions.
The primary types of diagnosis for Netherton syndrome include genetic testing, physical examination, and biopsy analysis. Genetic testing examines DNA for mutations in the SPINK5 gene to confirm the presence of Netherton syndrome, facilitating early diagnosis and informed treatment decisions. Treatment options include topical treatments, systemic therapies, phototherapy, and others. These treatments are available through various distribution channels, such as hospital pharmacies, retail pharmacies, online pharmacies, and others, and are used by different end-users, including hospitals, dermatology clinics, and research institutions.
The netherton syndrome market research report is one of a series of new reports from The Business Research Company that provides netherton syndrome market statistics, including the netherton syndrome industry global market size, regional shares, competitors with the netherton syndrome market share, detailed netherton syndrome market segments, market trends, and opportunities, and any further data you may need to thrive in the netherton syndrome industry. This netherton syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The netherton syndrome market size has grown rapidly in recent years. It will grow from $1.15 billion in 2024 to $1.27 billion in 2025 at a compound annual growth rate (CAGR) of 10.2%. The growth observed during the historical period can be attributed to factors such as increased awareness of rare genetic disorders, higher healthcare spending, growing awareness of Netherton syndrome, supportive government policies, and the rise of e-commerce and digital health platforms.
The netherton syndrome market size is expected to see rapid growth in the next few years. It will grow to $1.85 billion in 2029 at a compound annual growth rate (CAGR) of 10.0%. Looking ahead, the growth in the forecast period is expected to be driven by the increasing incidence of diabetes, greater internet penetration, the continued rise of e-commerce and digital health platforms, the growing prevalence of lamellar ichthyosis, and heightened awareness and support for rare diseases. Key trends for the forecast period include the development of targeted therapies, the expansion of clinical trials, advancements in diagnostic techniques, the adoption of telemedicine, and the growth of personalized medicine.
The increasing prevalence of genetic testing is expected to drive the growth of the Netherton syndrome market in the future. Genetic testing involves DNA analysis to identify changes, mutations, or variations linked to inherited traits, diseases, or medical conditions. The growing adoption of genetic testing is driven by greater awareness of hereditary diseases and the rising demand for personalized medicine. This surge in genetic testing enables the early and accurate diagnosis of Netherton Syndrome by detecting SPINK5 mutations, facilitating timely treatment and personalized care. It also improves patient management, genetic counseling, and overall outcomes. For instance, in April 2023, the National Institutes of Health (NIH) reported that in 2022, a total of 76,326 genetic tests were conducted worldwide, with 76,083 (99.7%) being clinical tests and 243 (0.3%) for research. As a result, the increasing prevalence of genetic testing is driving the growth of the Netherton syndrome market.
Companies in the Netherton syndrome market are focusing on developing advanced treatments, such as serine protease inhibitor-based topical lotions, to improve skin barrier function and reduce inflammation. These lotions are designed to block the action of serine proteases, enzymes involved in inflammation and immune response. By targeting these enzymes, the lotions help alleviate irritation and inflammation, providing relief for skin conditions such as Netherton Syndrome, where excessive inflammation causes skin discomfort. For example, in December 2024, Quoin Pharmaceuticals Ltd., a U.S.-based pharmaceutical company, received FDA clearance to begin a new clinical study for QRX003, a treatment for Netherton Syndrome. This study will evaluate up to eight patients applying QRX003 twice daily to over 80% of their body for 12 weeks, mimicking real-world use. QRX003 contains a broad-spectrum serine protease inhibitor targeting kallikreins, enzymes responsible for excessive skin shedding and inflammation in Netherton Syndrome, aiming to improve skin barrier function and reduce symptoms.
In July 2023, FarmaMondo Group, a Switzerland-based pharmaceutical company, partnered with Quoin Pharmaceuticals Inc. to commercialize QRX003 for Netherton syndrome in Singapore. This partnership aims to expand market access for QRX003, an innovative therapy currently in clinical development, providing new treatment options for patients with this rare condition. Quoin Pharmaceuticals Inc. is an Israel-based company developing potential therapies for Netherton syndrome.
Major players in the netherton syndrome market are Novartis AG, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Evotec AG, Fulgent Genetics, Invitae Corp., BioCryst Pharmaceuticals Inc., GeneDx, Prevention Genetics, Blueprint Genetics Oy, Medicover Hospitals, Quoin Pharmaceuticals Ltd., DNA Labs India, LifeMax Laboratories Inc., Krystal Biotech Inc., ResVita Bio, Azitra Inc, Dermelix Biotherapeutics, Sixera Pharma, MaRS Innovation.
North America was the largest region in the netherton syndrome market in 2024. The regions covered in netherton syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the netherton syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The netherton syndrome market consists of revenues earned by entities by providing services such as genetic testing, personalized treatment plans, genetic counseling services, medical treatments, and patient care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The netherton syndrome market includes sales of immunosuppressive drugs, oral medications, and genetic testing kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Netherton Syndrome Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on netherton syndrome market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for netherton syndrome ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The netherton syndrome market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.